|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013030,
umls-concept:C0021289,
umls-concept:C0034693,
umls-concept:C0171023,
umls-concept:C0205245,
umls-concept:C0597357,
umls-concept:C0871261,
umls-concept:C1280500,
umls-concept:C1517945,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-6-26
|
|
pubmed:abstractText |
Previous work has suggested that the therapeutic efficacy of olanzapine might be partially dependent on action at the D(1)-dopamine (DA) receptor site. Because early DA loss can lead to supersensitive D(1)-DA receptors, effects of olanzapine were investigated in adult rats given lesions to DA-containing neurons as neonates. In these animals, locomotor effects of SKF-38393 (a D(1)-DA agonist) were attenuated by olanzapine, but at doses (5 and 10 mg/kg) that decreased activity when given alone. Olanzapine prevented induction of striatal Fos protein by SKF-38393 and partially attenuated the long-term "priming" effect of repeated SKF-38393 treatment. Olanzapine also antagonized the stimulant effects of quinpirole (a D(2)-type DA agonist) in animals lesioned as young adults, at doses lower than those necessary to antagonize SKF-38393-induced activity. In addition, olanzapine antagonized apomorphine-induced self-injurious behavior in neonate-lesioned rats in a dose-related fashion. Attenuation of self-injury in this animal model suggests that olanzapine should be tested against this symptom in patient populations.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2,3,4,5-Tetrahydro-7,8-dihydroxy-1-p...,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Apomorphine,
http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidopamine,
http://linkedlifedata.com/resource/pubmed/chemical/Pirenzepine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D1,
http://linkedlifedata.com/resource/pubmed/chemical/olanzapine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0893-133X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
224-33
|
|
pubmed:dateRevised |
2011-5-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11425506-2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine,
pubmed-meshheading:11425506-Adrenergic Agents,
pubmed-meshheading:11425506-Animals,
pubmed-meshheading:11425506-Animals, Newborn,
pubmed-meshheading:11425506-Antipsychotic Agents,
pubmed-meshheading:11425506-Apomorphine,
pubmed-meshheading:11425506-Benzodiazepines,
pubmed-meshheading:11425506-Corpus Striatum,
pubmed-meshheading:11425506-Dopamine,
pubmed-meshheading:11425506-Dopamine Agonists,
pubmed-meshheading:11425506-Female,
pubmed-meshheading:11425506-Male,
pubmed-meshheading:11425506-Motor Activity,
pubmed-meshheading:11425506-Oxidopamine,
pubmed-meshheading:11425506-Pirenzepine,
pubmed-meshheading:11425506-Rats,
pubmed-meshheading:11425506-Rats, Sprague-Dawley,
pubmed-meshheading:11425506-Receptors, Dopamine D1
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Effect of olanzapine on functional responses from sensitized D1-dopamine receptors in rats with neonatal dopamine loss.
|
|
pubmed:affiliation |
Department of Psychiatry, Skipper Bowles Center for Alcohol Studies, University of North Carolina School of Medicine, Chapel Hill 27599-7178, USA. sheryl.moy@css.unc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
